Nuo Therapeutics, Inc. (AURX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 2M 4M 6M Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 38.2K Q4 '22: 112.2K Q1 '23: 173.3K Q2 '23: 291.5K Q3 '23: 485.5K Q4 '23: 608.5K Q1 '24: 782K Q2 '24: 1M Q3 '24: 1.2M Q4 '24: 1.4M Q1 '25: 1.6M Q2 '25: 2M Q3 '25: 2.6M Q4 '25: 3.3M Q1 '26: 4.1M Q2 '26: 5.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 1.5M 3M 4.5M Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 31.8K Q4 '22: 93K Q1 '23: 143.7K Q2 '23: 241.4K Q3 '23: 388.1K Q4 '23: 482.4K Q1 '24: 615.7K Q2 '24: 817.5K Q3 '24: 909.5K Q4 '24: 1.1M Q1 '25: 1.2M Q2 '25: 1.5M Q3 '25: 1.8M Q4 '25: 2.2M Q1 '26: 2.7M Q2 '26: 3.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income TTM

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '21: -342.7K Q4 '21: -90.7K Q1 '22: -606.8K Q2 '22: -1.5M Q3 '22: -2.4M Q4 '22: -3.3M Q1 '23: -3.7M Q2 '23: -3.6M Q3 '23: -3.5M Q4 '23: -3.2M Q1 '24: -3M Q2 '24: -2.7M Q3 '24: -2.5M Q4 '24: -2.5M Q1 '25: -2.5M Q2 '25: -2.6M Q3 '25: -2.6M Q4 '25: -2.5M Q1 '26: -2.2M Q2 '26: -1.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-6M -3M 0 3M 6M 9M Q3 '21: 7.5M Q4 '21: -90.7K Q1 '22: -460.3K Q2 '22: -1.4M Q3 '22: -2.3M Q4 '22: -3.2M Q1 '23: -3.7M Q2 '23: -3.6M Q3 '23: -3.5M Q4 '23: -3.2M Q1 '24: -3M Q2 '24: -2.7M Q3 '24: -2.5M Q4 '24: -2.3M Q1 '25: -2.4M Q2 '25: -2.5M Q3 '25: -2.4M Q4 '25: -2.5M Q1 '26: -2.4M Q2 '26: -2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 700K 1.4M 2.1M Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 6.5K Q4 '22: 19.2K Q1 '23: 29.6K Q2 '23: 50.1K Q3 '23: 97.4K Q4 '23: 126.1K Q1 '24: 166.3K Q2 '24: 211.1K Q3 '24: 257.8K Q4 '24: 302.8K Q1 '25: 373.3K Q2 '25: 467.3K Q3 '25: 773.5K Q4 '25: 1.1M Q1 '26: 1.4M Q2 '26: 1.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '21: -46.6K Q4 '21: -120K Q1 '22: -853.1K Q2 '22: -2M Q3 '22: -3M Q4 '22: -3.7M Q1 '23: -3.8M Q2 '23: -3.5M Q3 '23: -3.3M Q4 '23: -3.2M Q1 '24: -2.9M Q2 '24: -2.7M Q3 '24: -2.4M Q4 '24: -2.2M Q1 '25: -1.7M Q2 '25: -713.8K Q3 '25: -932.9K Q4 '25: -865K Q1 '26: -1.7M Q2 '26: -2.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '21: -46.6K Q4 '21: -120K Q1 '22: -865K Q2 '22: -2M Q3 '22: -3M Q4 '22: -3.8M Q1 '23: -3.8M Q2 '23: -3.5M Q3 '23: -3.3M Q4 '23: -3.2M Q1 '24: -2.9M Q2 '24: -2.7M Q3 '24: -2.6M Q4 '24: -2.4M Q1 '25: -2.1M Q2 '25: -1.1M Q3 '25: -1.2M Q4 '25: -1.1M Q1 '26: -1.7M Q2 '26: -2.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '20: 30.5M Q2 '20: 24.2M Q3 '20: 24.2M Q1 '21: 30.3M Q2 '21: 30.3M Q3 '21: 30.3M Q1 '22: 37.1M Q2 '22: 39.8M Q3 '22: 41.1M Q1 '23: 41.8M Q2 '23: 41.8M Q3 '23: 42.1M Q1 '24: 44.2M Q2 '24: 44.7M Q3 '24: 45.6M Q1 '25: 46.8M Q2 '25: 46.8M Q3 '25: 47.5M Q1 '26: 48.3M Q2 '26: 48.4M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.10 0.00 0.10 0.20 0.30 Q3 '21: 0.28 Q4 '21: -0.03 Q1 '22: -0.04 Q2 '22: -0.06 Q3 '22: -0.08 Q4 '22: -0.07 Q1 '23: -0.08 Q2 '23: -0.08 Q3 '23: -0.08 Q4 '23: -0.08 Q1 '24: -0.08 Q2 '24: -0.07 Q3 '24: -0.06 Q4 '24: -0.05 Q1 '25: -0.05 Q2 '25: -0.05 Q3 '25: -0.05 Q4 '25: -0.05 Q1 '26: -0.04 Q2 '26: -0.04 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.